- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
Walking The Tight Rope: A Discussion Of Striking The Right Balance In Depression, With A Focus On Norepinephrine
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Walking The Tight Rope: A Discussion Of Striking The Right Balance In Depression, With A Focus On Norepinephrine
Join us for a PsychU webinar with Drs. Vladimir Maletic, Craig Chepke, and Jason Carter as they discuss the potential role of norepinephrine in Major Depressive Disorder, as part of the monoaminergic theory of depression.
Despite the efficacy of first-line anti-depressant treatments in MDD, many individuals continue to experience unresolved symptoms that may impair their daily functioning and increase the healthcare burden. In fact, the STAR*D study demonstrated approximately one third of patients with MDD achieved remission following treatment with first-line antidepressants, highlighting the need to address unresolved and persistent symptoms of depression.1 Recent studies have shown that norepinephrine, a neurotransmitter which regulates concentration, energy levels, and arousal, may play a crucial role in the persistence of depression symptoms.2
Our webinar aims to provide valuable insights into the complex nature of depression and the potential role of norepinephrine in the pathophysiology of depression.
References:- Rush AJ et al. Am J Psychiatry. 2006;163:1905-1917
- Maletic V, et al. Front Psychiatry. 2017;8:42.
Featuring
Vladimir Maletic, MD
Serves as Clinical Professor, Psychiatry/Behavioral Science, University of South Carolina School of Medicine Greenville, SC
MoreVladimir Maletic, MD serves as Clinical Professor, Psychiatry/Behavioral Science, School of Medicine Greenville, SC and has been rated as Best Doctors of the America Registry and Psychiatrist of the year. Dr. Maletic received the Upjohn Achievement Award and Student Council teaching award and faculty award for teaching achievement. He also has received the Medical School Award for Academic Achievement.Craig Chepke, MD, FAPA
Board-Certified Psychiatrist, Fellow of the American Psychiatric Association, Private practice at Excel Psychiatric Associates in Huntersville, NC, Adjunct Associate Professor of Psychiatry for Atrium Health and University of North Carolina School of Medicine
MoreExcel Psychiatric Associates, Atrium Health, and University of North Carolina School of Medicine Dr. Chepke is a Board-Certified psychiatrist and a Fellow of the American Psychiatric Association. He has a private practice at Excel Psychiatric Associates in Huntersville, NC and serves as an Adjunct Associate Professor of Psychiatry for Atrium Health and an Adjunct Assistant Professor of Psychiatry for the University of North Carolina School of Medicine. He has special interests in treatment-resistant and severe mental illness, movement disorders, ADHD, and sleep medicine. Dr. Chepke is a member of the Huntington Study Group and serves on the board of directors for the CURESZ foundation, a nonprofit organization dedicated to improving the lives of people living with SchizophreniaJason Carter, PharmD (OPDC)
Senior Medical Science Liaison, Neuroscience Field Medical Affairs
Vladimir Maletic and Craig Chepke are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Jason Carter is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Related Events
-
Improving Quality Of Life, Functioning & Well-being In Individuals Living With Bipolar Disorder
July 25 12:00 pm to 1:00 pm
Registration
Related Resources
-
Practical Application of Wellness Strategies for Individuals in Underserved Communities with Major Depressive Disorder (MDD) & Post-Traumatic Stress Disorder (PTSD)
On-Demand Webinar July 12, 2024Approximately 50 million United States adults are living with a mental illness, with 21 million having depression and 13 million with post-traumatic stress disorder.1-4 Minority individuals are among these prevalence…
-
Talking Points (Part I): Primary Care on PTSD – David Lewis
Podcast July 10, 2024Listen to Amica Simmons-Yon, PharmD, PhD as she spills the tea on a new Talking Points Series from Primary Care on Post-Traumatic Stress Disorder (PTSD) with special guest, David E….
-
Primary Care PTSD Screen For DSM-5 (PC-PTSD-5)
Downloadable Resource June 27, 2024The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5) is a 5-item screen designed to identify individuals with probable PTSD in primary care settings. The measure begins with an item which assesses lifetime…
Join today for instant access to all PsychU content, events, and more!
Membership is free!
"*" indicates required fields
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: